Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.

Stacey E TarvinMatthew A Sherman Hanna KimNayimisha BalmuriAmanda G BrownAlbert ChowHarry L GewanterMarietta M de GuzmanAdam M HuberSusan KimMarisa S Klein-GitelmanMegan Mariko PerronAngela Byun RobinsonSara E SabbaghSonia SavaniSusan ShenoiJacob SpitznagleCory StinglGrant SyversonHeather ToryCharles Spencernull null

Published in: Arthritis care & research (2024)

CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.

Keyphrases

rheumatoid arthritis
disease activity
interstitial lung disease
early onset
clinical practice
primary care
healthcare
drug induced
juvenile idiopathic arthritis
emergency department
adverse drug
young adults
smoking cessation
childhood cancer